Literature DB >> 10921511

Short-term benefit from oral vancomycin treatment of regressive-onset autism.

R H Sandler1, S M Finegold, E R Bolte, C P Buchanan, A P Maxwell, M L Väisänen, M N Nelson, H M Wexler.   

Abstract

In most cases symptoms of autism begin in early infancy. However, a subset of children appears to develop normally until a clear deterioration is observed. Many parents of children with "regressive"-onset autism have noted antecedent antibiotic exposure followed by chronic diarrhea. We speculated that, in a subgroup of children, disruption of indigenous gut flora might promote colonization by one or more neurotoxin-producing bacteria, contributing, at least in part, to their autistic symptomatology. To help test this hypothesis, 11 children with regressive-onset autism were recruited for an intervention trial using a minimally absorbed oral antibiotic. Entry criteria included antecedent broad-spectrum antimicrobial exposure followed by chronic persistent diarrhea, deterioration of previously acquired skills, and then autistic features. Short-term improvement was noted using multiple pre- and post-therapy evaluations. These included coded, paired videotapes scored by a clinical psychologist blinded to treatment status; these noted improvement in 8 of 10 children studied. Unfortunately, these gains had largely waned at follow-up. Although the protocol used is not suggested as useful therapy, these results indicate that a possible gut flora-brain connection warrants further investigation, as it might lead to greater pathophysiologic insight and meaningful prevention or treatment in a subset of children with autism.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10921511     DOI: 10.1177/088307380001500701

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  156 in total

Review 1.  The pathophysiology and treatment of autism.

Authors:  D J Posey; C J McDougle
Journal:  Curr Psychiatry Rep       Date:  2001-04       Impact factor: 5.285

Review 2.  Dysbiosis and the immune system.

Authors:  Maayan Levy; Aleksandra A Kolodziejczyk; Christoph A Thaiss; Eran Elinav
Journal:  Nat Rev Immunol       Date:  2017-03-06       Impact factor: 53.106

3.  Sydney M. Finegold.

Authors: 
Journal:  J Clin Microbiol       Date:  2012-05-23       Impact factor: 5.948

Review 4.  Gut microbial communities modulating brain development and function.

Authors:  Maha Al-Asmakh; Farhana Anuar; Fahad Zadjali; Joseph Rafter; Sven Pettersson
Journal:  Gut Microbes       Date:  2012-06-29

Review 5.  Immune dysfunction in autism: a pathway to treatment.

Authors:  Milo Careaga; Judy Van de Water; Paul Ashwood
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 6.  Immune therapy in autism: historical experience and future directions with immunomodulatory therapy.

Authors:  Michael G Chez; Natalie Guido-Estrada
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 7.  Gut microbiome in health and disease: Linking the microbiome-gut-brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases.

Authors:  Shivani Ghaisas; Joshua Maher; Anumantha Kanthasamy
Journal:  Pharmacol Ther       Date:  2015-11-26       Impact factor: 12.310

8.  The Brain-Gut-Microbiome Axis: What Role Does It Play in Autism Spectrum Disorder?

Authors:  Ruth Ann Luna; Tor C Savidge; Kent C Williams
Journal:  Curr Dev Disord Rep       Date:  2016-02-26

Review 9.  Autism spectrum disorders and intestinal microbiota.

Authors:  Maria De Angelis; Ruggiero Francavilla; Maria Piccolo; Andrea De Giacomo; Marco Gobbetti
Journal:  Gut Microbes       Date:  2015

10.  A double-blind, placebo-controlled trial of oral human immunoglobulin for gastrointestinal dysfunction in children with autistic disorder.

Authors:  Benjamin L Handen; Raun D Melmed; Robin L Hansen; Michael G Aman; David L Burnham; Jon B Bruss; Christopher J McDougle
Journal:  J Autism Dev Disord       Date:  2009-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.